Bipoláris zavar: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• GLP-1 0
• BDNF 0
• NMDA 1
• SGLT2 1
• PI3K 0
• AQP4 0
• PCSK9 0
• PPAR 0
• TNF 0
• AKT 0
• BRD4 0
• G6PD 0
• IGF1R 0
• IL-1 0
• IL-17 0
• IL-6 0
• MAPT 0
• NLRP3 0
• NRF2 0
• SIRT1 0
• TFEB 0

1446 intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  The cerebellum: a transdiagnostic personalised target for neuromodulation in psychiatry (CLOVIS)

  Universite Paris Xii Val de Marne· Creteil, Franciaország· EU contribution 1 499 500 EUR· until 2031. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  Callyope Copilot: Speech Foundation Model for Transdiagnostic Mental Health Assessment & Relapse Mitigation (CALLYOPECOPILOT)

  Callyope· Neuilly sur Seine, Franciaország· EU contribution 2 498 053 EUR· until 2028. máj.

• European Commission (Horizon Europe) · HORIZON-ERC

  Personalized Genetic Risk Profile: A New Tool to Guide Prevention of Serious Mental Illness (PersonalRiskProfile)

  Stichting Amsterdam Umc· Amsterdam, Hollandia· EU contribution 1 499 891 EUR· until 2030. dec.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Synaptic signatures: Understanding thalamocortical circuit specification and disease vulnerability (ThalamoLinkIT)

  Vib Vzw· Zwijnaarde - Gent, Belgium· EU contribution 200 400 EUR· until 2027. márc.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  Synapsing Mental Disorders and Neurodegenerative diseases: Towards more effective diagnosis and management of psychiatric symptoms (SYNAPSING)

  Institut de Recerca de L'hospital de la Santa Creu I Sant Pau Fundacion· Barcelona, Spanyolország· EU contribution 6 999 922 EUR· until 2029. dec.· 9 countries

5 of 10 running projects, newest first. Listed amounts together: 29,5 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure

  NCT05603104· Dr. Inge Winter· Frissítve: 2026. nov. 5.

  “The site in Israel stopped recruitment due to logistic reasons. Other sites are recruiting for 2023-506602-39-00, 2023-506605-19-00, 2023-506617-21-00.”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

  NCT04031469· ProgenaBiome· Frissítve: 2026. szept. 21.

  “Administrative”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  A Pilot Study Investigating the Efficacy of Minocycline and N-Acetyl Cysteine for Bipolar Depression

  NCT02719392· Massachusetts General Hospital· Frissítve: 2026. júl. 24.

  “Study did not receive funding and was never carried out.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Brain Circuitry Analysis in Bipolar Disorder

  NCT05186077· Jennifer Sweet· Frissítve: 2026. júl. 6.

  “The original funding for this study ended and we were not able to secure new funding to continue”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  IM Ketamine vs Midazolam for Suicidal ER Patients

  NCT04640636· New York State Psychiatric Institute· Frissítve: 2026. máj. 26.

  “The U.S. Department of Health and Human Services (HHS) Office of Human Research Protections (OHRP) issued an FWA restriction on NYSPI research that also included a pause of human subjects research as of June 23, 2023.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Dopamine D3 Receptor Occupancy in Bipolar Depression

  NCT05060549· New York State Psychiatric Institute· Frissítve: 2026. ápr. 14.

  “Funding decision”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Alexithymia Intervention for Suicide

  NCT05724953· VA Office of Research and Development· Frissítve: 2026. márc. 27.

  “Staff turnover and trouble with recruitment, staffing, and paying invoices.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Lifestyle MIND- Feasibility of Wait-list Control

  NCT06384521· The University of Texas Health Science Center at San Antonio· Frissítve: 2026. márc. 12.

  “No funding obtained”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Braining- Aerobic Physical Activity as Add on Treatment in Bipolar Depression

  NCT05340686· Region Stockholm· Frissítve: 2026. febr. 10.

  “Difficulties recruiting”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Pilot Study 1: Efficacy and Safety of Sublingual Dexmedetomidine (BXCL501) for the Treatment of Agitation in the Emergency Department

  NCT05974527· Brigham and Women's Hospital· Frissítve: 2026. jan. 28.

  “Study did not start - due to funding issues prior to IRB approval”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Examining Neurobiological Mechanisms Underlying the Therapeutic Effect of the Ketogenic Diet in Bipolar Disorder (BD)

  NCT06081426· University of Pittsburgh· Forrás

• Seeing the Light: Early Intervention in People at Risk for Bipolar Disorder

  NCT06282250· Geestelijke Gezondheidszorg Eindhoven (GGzE)· Forrás

• A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)

  NCT06951711· Bristol-Myers Squibb· Forrás

• Natural History of Depression, Bipolar Disorder and Suicide Risk

  NCT06462196· National Institute of Mental Health (NIMH)· Forrás

• Safety and Feasibility of DBS for Bipolar Depression

  NCT07745374· Icahn School of Medicine at Mount Sinai· Forrás

• Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure

  NCT05603104· Dr. Inge Winter· Forrás

• A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)

  NCT07286175· Eli Lilly and Company· Forrás

• A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

  NCT07140913· Bristol-Myers Squibb· Forrás

• Effects of Theta Burst Stimulation on the Brain, Behavior, and Clinical Symptoms in Adults With Bipolar Disorder

  NCT04696471· Mary Phillips, MD MD (Cantab)· Forrás

• A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

  NCT06929273· Bristol-Myers Squibb· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 6
• Mendelian Randomization Analysis 52
• CRISPR-Cas Systems 2
• Gene Expression Profiling 23
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 2
• Exome Sequencing 3
• Proteomics 17
• Metabolomics 8
• Mass Spectrometry 3
• Immunohistochemistry 1
• Positron-Emission Tomography 13
• Magnetic Resonance Imaging 190
• Machine Learning 59
• Deep Learning 9
• Cohort Studies 96
• Genome-Wide Association Study 107

• Sibling Psychiatric Diagnoses and Risk of Postpartum Psychosis: A Nationwide Cohort Study.

  J Clin Psychiatry, 2026. nov.

• Tirzepatide Initiation in Lithium-Treated Bipolar Disorder: Renal Biomarker Trajectories and Lithium Safety Signals Over 12 Months in a Real-World Cohort.

  Hum Psychopharmacol, 2026. nov.

• Comparative Effectiveness of Lithium- Vs. Valproate-Based Combinations With Atypical Antipsychotics in Preventing Rehospitalization After a First Manic Episode of Bipolar I Disorder.

  Bipolar Disord, 2026. nov.

• Is It Possible to Establish Thresholds for Depressive Symptom Severity Associated With Cognitive Impairments in Bipolar Disorders? Findings From the FACE-BD Cohort.

  Depress Anxiety, 2026. okt.

• Exposure to residential greenness and subsequent risk of common mental disorders among individuals with COVID-19 in South Korea: A nationwide cohort study.

  PLoS One, 2026. okt.

• Immunomodulatory effects of lithium treatment in bipolar disorder: A prospective cohort study.

  Prog Neuropsychopharmacol Biol Psychiatry, 2026. okt.

• Association of plasmatic lipids and suicidal ideation in bipolar disorders: a FACE-BD cohort study.

  Eur Neuropsychopharmacol, 2026. szept.

• Association between school achievement in upper secondary education and subsequent risk of mental disorders: a population-based cohort study.

  Psychol Med, 2026. szept.

• Increased risk of bipolar disorder following Parkinson's disease: A nationwide population-based cohort study.

  J Psychiatr Res, 2026. szept.

• Association of lithium versus valproate initiation with all-cause mortality and incident dementia: a multinational real-world cohort study.

  Front Neurol, 2026. szept.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.